Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $30.2752W HIGH $73.30
Volume
468.21 K
Value Traded
23.52 M
Short % Float
18.75%
Days to Cover
8.2
-1.04%Week
-4.07%1 Month
-9.1%3 Month
-26.82%6 Month
+255.05%5 Year
+459.86%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.46 B
EPS (TTM)
4.78
P/E Ratio
10.20
Ent. Value
1.29 B
Total Shares
29.90 M
Float Shares
27.92 M
Insiders
6.62%
Institutions
102.75%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ANAB Catalyst Timeline
Dated clinical, regulatory and corporate events for AnaptysBio, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for AnaptysBio, Inc.
348Total events
12Upcoming
112Tier-1 (high impact)
2016 to 2029Coverage
Upcoming catalysts 2
Event history 50
●IP Litigation RulingIP / Competition
GSK and Tesaro to file answering post-trial brief on or before September 25, 2026
●Quarterly UpdateCorporate
Anaptys reported Q2 and transitional fiscal year 2026 financial results
●IP Litigation RulingIP / Competition
Anaptys filed opening post-trial brief on August 21, 2026
▲EU Orphan DesignationimsidolimabEx-US Regulatory
European Commission granted Orphan Designation for imsidolimab in GPP
generalized pustular psoriasis (GPP)source ↗
●IP Litigation RulingIP / Competition
Trial held before Delaware Chancery Court in Anaptys v. GSK/Tesaro litigation
●Legal / SettlementCorporate
GSK and Tesaro litigation trial held before Delaware Chancery Court
●IP Litigation RulingIP / Competition
Trial held before Delaware Chancery Court in Anaptys litigation with GSK and Tesaro
●IP Litigation RulingIP / Competition
GSK and Tesaro litigation trial held before Delaware Chancery Court
●Management ChangeCorporate
Appointment of Susannah Gray and Owen Hughes to Board of Directors
◆Oral PresentationPresentation
Fireside chat at H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
▲IP Litigation RulingIP / Competition
Delaware Chancery Court dismisses Tesaro's anticipatory breach claim against Anaptys
●Restructuring LayoffsCorporate
Separation of AnaptysBio and First Tracks Biotherapeutics completed
▼Equity OfferingCorporate
First Tracks Bio secures $145 million private placement commitments
◆FDA ApprovalZejulaFDA Decision
Potential FDA approval of Zejula for endometrial cancer triggers $10M milestone
endometrial cancersource ↗
▲Milestone PaymentCorporate
Anticipated $75 million commercial sales milestone from Tesaro upon Jemperli achieving $1 billion in worldwide net sales
solid tumorssource ↗
◆Topline ReadoutRosnilimabClinical Data
Phase 2 top-line data through Week 12 for rosnilimab in ulcerative colitis
ulcerative colitissource ↗
▼Primary Endpoint MissedRosnilimabClinical Data
Rosnilimab did not meet primary endpoint of mean change from baseline in modified Mayo Score at Week 12
moderate-to-severe ulcerative colitissource ↗
▼Trial DiscontinuedRosnilimabTrial
UC trial discontinued due to lack of efficacy
moderate-to-severe ulcerative colitissource ↗
▲Oral PresentationRosnilimabPresentation
Late-breaking presentation of Phase 2b data in RA at ACR Convergence 2025
rheumatoid arthritissource ↗
◆Topline ReadoutRosnilimabClinical Data
Top-line data through Week 12 expected
ulcerative colitissource ↗
▲Oral PresentationRosnilimabPresentation
Late-breaking oral presentation of Phase 2b RENOIR trial results at ACR Convergence 2025
rheumatoid arthritissource ↗
◆Late-BreakerRosnilimabPresentation
Late-breaking oral presentation of complete Phase 2b data for rosnilimab in RA at ACR Convergence 2025
rheumatoid arthritissource ↗
◆Full ResultsRosnilimabClinical Data
Complete Phase 2b data for rosnilimab in RA presented at ACR Convergence 2025
rheumatoid arthritissource ↗
◆Topline ReadoutRosnilimabClinical Data
Initial data from Phase 2 UC study expected
ulcerative colitissource ↗
▲Full ResultsRosnilimabClinical Data
Updated Phase 2b data through six months announced
rheumatoid arthritissource ↗
●R&D DayRosnilimabPresentation
Investor call and webcast to review Phase 2b RA data
rheumatoid arthritissource ↗
◆Topline ReadoutANB032Clinical Data
Top-line interim data from Phase 2b trial for ANB032 in AD
atopic dermatitissource ↗
◆Topline ReadoutANB032Clinical Data
Top-line week 14 data from Phase 2b trial for ANB032 in AD
moderate-to-severe atopic dermatitis (AD)source ↗
◆Topline ReadoutcobolimabClinical Data
Top-line data from COSTAR Lung Phase 3 trial for cobolimab plus dostarlimab
advanced NSCLCsource ↗
◆Topline ReadoutimsidolimabClinical Data
Top-line data from interim analysis of GEMINI-1 Phase 3 trial
generalized pustular psoriasis (GPP)source ↗
◆Trial InitiationRosnilimabTrial
Initiation of second Phase 2 trial for rosnilimab in new indication
to be announcedsource ↗
Past FDA Catalysts and PDUFA Decisions
How ANAB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-10-29 | Rosnilimab | Phase 2b data presentation | Phase 2b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 54%
Micro Cap(rank 355 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Rosnilimab Monoclonal antibodyNCT06041269 | Rheumatoid Arthritis | Phase 2 | ACTIVE NOT_RECRUITING | 420 | May 30, 2025 | ||||||
| Rosnilimab Monoclonal antibodyNCT06127043 | Ulcerative Colitis | Phase 2 | ACTIVE NOT_RECRUITING | 132 | May 1, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every ANAB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| rosnilimab | moderate-to-severe ulcerative colitis | Phase 2 | 2025-11-10 | clinical remission 400mg Q4W: 7%; clinical remission 800mg Q2W: 7%; endoscopic remission 400mg Q4W: 5%; endoscopic remission 800mg Q2W: 4%; baseline mean m MS score: 6.7; adverse events: >5%Read More | Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative ColitisRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| RENTON HOLLINGSDirector | Option | 5,000 15,995 held | $18.03 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ANAB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 25.9 % (40 %) | 531.91 M | 7.88 M |
ANAB Institutional Ownership Trends
ANAB Short Interest
Shares sold short, counted twice a month.
18.75%
Short % of Float
of tradable shares sold short
5.2M
Shares Sold Short
-3.7% vs prior count
8.2 High
Days to Cover
trading days of normal volume to buy every short share back
639.5K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ANAB ranks across every disease it competes in
Competitive Position is a premium feature
See how ANAB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialANAB News
ANABJemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer
AnaptysBio's Jemperli (dostarlimab) has received FDA approval as the first immunotherapy for adults with locally advanced rectal cancer characterized by microsatellite instability-high (MSI-H) and mismatch repair deficiency (dMMR). The approval is based on promising data from the AZUR-1 trial, showing a significant percentage of patients achieving sustained clinical responses. This treatment option may help patients avoid traditional therapies like chemotherapy and surgery, with ongoing safety monitoring.
Read more →ANABAnaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update
AnaptysBio reported strong financial results for Q2 2026, with Jemperli achieving $644 million in global net sales, reflecting a 34% year-over-year growth. Positive interim results from the AZUR-1 trial for locally advanced rectal cancer were announced, with an FDA action date set for February 2027. The company is also involved in litigation with GSK and Tesaro, with a judgment expected in late 2026 or early 2027.
Read more →ANABAnaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference
AnaptysBio, Inc. announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 15, 2026. CFO Chris Murphy will present at 3:30 PM ET, and a live webcast will be available on the company's investor website. A replay of the presentation will be accessible for 30 days post-event.
Read more →ANABAnaptys Announces First Quarter 2026 Financial Results and Provides Business Update
AnaptysBio reported its financial results for Q1 2026, highlighting a successful spin-off of First Tracks Biotherapeutics and strong sales growth for Jemperli. The company appointed Chris Murphy as CFO and added two experienced members to its Board of Directors. Despite a net loss increase, the company aims to protect its royalty streams and deliver value to shareholders.
Read more →ANABAnaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
AnaptysBio has appointed Christopher Murphy as Chief Financial Officer and Owen Hughes to its Board of Directors. These appointments aim to enhance the company's leadership team with expertise in finance, business development, and royalty management. The CEO expressed confidence that these additions will help protect and enhance shareholder value.
Read more →ANABAnaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
AnaptysBio, Inc. will have its CEO, Daniel Faga, participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on May 6, 2026. The discussion aims to highlight the company's financial collaborations, particularly with GSK and Vanda. This event is an opportunity for investors to gain insights into AnaptysBio's strategies and future directions.
Read more →ANAB▲ +14.8%on this news· ran to +30% by day 1
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim
The Delaware Chancery Court has dismissed Tesaro's anticipatory breach claim against AnaptysBio, affirming Anaptys' position on the Collaboration Agreement. This ruling preserves the current royalty rates and sets a trial date for July 2026 to address Anaptys' contract claims against Tesaro and GSK. Anaptys is confident in its legal stance and aims to protect its interests in the Jemperli royalty stream.
Read more →ANAB▼ -24.5%on this news
Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations
AnaptysBio has completed the spin-off of First Tracks Biotherapeutics, transitioning to a focus on managing royalties from Jemperli and imsidolimab. The company will operate under a virtual model with minimal expenses and aims for a high EBIT margin. This strategic shift is designed to enhance shareholder value while navigating inherent risks associated with financial collaborations.
Read more →ANABFirst Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement
AnaptysBio announced a $145 million private placement for its spin-off, First Tracks Biotherapeutics. The placement involves the sale of nearly 5.8 million shares at $13.81 each, expected to close upon the completion of the spin-off on April 20, 2026. Proceeds will be used for general corporate purposes, including clinical development of ANB033.
Read more →ANABAnaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics
AnaptysBio, Inc. has approved the spin-off of First Tracks Biotherapeutics, which will begin trading on Nasdaq under the ticker TRAX on April 20, 2026. First Tracks Bio aims to develop next-generation antibody therapeutics for autoimmune diseases, with three lead candidates in various clinical trial phases. This strategic separation is intended to enhance focus and value for both companies.
Read more →ANABAnaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update
AnaptysBio, Inc. has announced a $100 million stock repurchase plan authorized by its Board of Directors. This decision follows the upcoming spin-off of First Tracks Biotherapeutics, which is set for April 20, 2026. The company aims to manage financial collaborations effectively while minimizing operating expenses. Additionally, Susannah Gray has been appointed to the Board, bringing valuable expertise to the company.
Read more →ANAB▲ +14.6%on this news
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results
AnaptysBio, Inc. announced plans to spin-off its biopharma operations into a new public company, First Tracks Biotherapeutics, aiming to enhance investor value. The company reported strong financial results for Q4 and the full year 2025, highlighting the promising potential of its pipeline assets, including ANB033, currently in Phase 1b trials. However, the separation process carries inherent risks and uncertainties.
Read more →ANAB▲ +5.2%on this news
Anaptys Announces $100 Million Stock Repurchase Plan
AnaptysBio, Inc. has announced a $100 million stock repurchase plan, expanding its existing program. The company expects to end 2025 with around $300 million in cash, bolstered by a potential $75 million milestone from GSK. The repurchase plan will run until March 31, 2026, but may be adjusted based on market conditions.
Read more →ANAB▲ +5.2%on this newsshared move
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
AnaptysBio has filed a Verified Complaint against Tesaro, alleging breach of their Collaboration Agreement and tortious interference by GSK. The lawsuit seeks a court declaration affirming Anaptys' rights under the agreement. This follows a history of disputes between the companies, including a previous settlement. The trial is expected in July 2026.
Read more →ANAB▼ -14.3%on this news
Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis
AnaptysBio announced that its Phase 2 trial for rosnilimab in ulcerative colitis failed to meet primary and secondary endpoints at Week 12. The company will discontinue the trial, which saves at least $10 million. Rosnilimab showed expected pharmacology but lacked adequate efficacy compared to placebo. Anaptys plans to update progress on rosnilimab for rheumatoid arthritis in the first half of 2026.
Read more →ANABAnaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
AnaptysBio announced plans to split its biopharma operations from royalty assets by the end of 2026. The company expects to record a one-time $75 million milestone payment from GSK in the fourth quarter. This payment triggers after Jemperli reaches $1 billion in global net sales. GSK reported third-quarter Jemperli sales of $303 million, bringing year-to-date revenue to $785 million.
Read more →ANABAnaptys Announces Participation in November Investor Conferences
AnaptysBio, Inc. has announced its participation in several upcoming investor conferences, including the TD Cowen Immunology & Inflammation Summit and the Guggenheim Healthcare Innovation Conference. CEO Daniel Faga and other executives will represent the company at these events. Webcasts of the presentations will be available for 30 days post-conference, promoting transparency and investor engagement.
Read more →About AnaptysBio, Inc.
Headquarters10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA, 92121
Founded2005
BIOPHARMAWATCH ELITE PLUS
Trade the next ANAB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime